{"ModuleTitle": "Company Description", "CompanyName": "Sorrento Therapeutics, Inc.", "Symbol": "SRNE", "Address": "4955 DIRECTORS PLACE, SAN DIEGO, California, 92121, United States of America", "Phone": "858-203-4100", "Industry": "Biotechnology: Biological Products (No Diagnostic Substances)", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Sorrento Therapeutics, Inc. (Nasdaq: SRNE), together with its subsidiaries\r\n(collectively, the \"Company\", \"we\", \"us\" and \"our\") is a clinical stage and\r\ncommercial biopharma company focused on delivering innovative and clinically\r\nmeaningful therapies to patients and their families to address unmet medical\r\nneeds. We also have programs assessing the use of our technologies and products\r\nin autoimmune, inflammatory and neurodegenerative diseases.\r\nAt our core, we are an antibody-centric company and leverage our proprietary\r\nG-MAB(TM) library and targeted delivery modalities to generate the next generation\r\nof cancer therapeutics. Our fully human antibodies include PD-1, PD-L1, CD38,\r\nCD123, CD47, CTLA-4, c-MET, VEGFR2, CCR2 and CD137 among others.\r\nOur vision is to leverage these antibodies in conjunction with proprietary\r\ntargeted delivery modalities to generate the next generation of cancer\r\ntherapeutics.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f03%2f0000850261-20-000027.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Henry H. Ji", "title": "Chairman, President & Chief Executive Officer"}, {"name": "Jiong Shao", "title": "Chief Financial Officer & Executive Vice President"}, {"name": "Stephen L Klincewicz", "title": "VP-Pharmacovigilance & Clinical Operations"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}